129 results on '"Labrador ‐ Horrillo, M."'
Search Results
2. Buckwheat-Induced Refractory Anaphylaxis in a Hospitalized Patient
- Author
-
Domínguez Estirado, A, primary, Cuevas Bravo, C, additional, Skrabski, F, additional, Baptista Serna, L, additional, Bartolomé Zavala, B, additional, Labrador-Horrillo, M, additional, and Tornero Molina, P, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study
- Author
-
Maurer, M., Houghton, K., Costa, C., Dabove, F., Ensina, L.F., Giménez-Arnau, A., Guillet, G., Konstantinou, G.N., Labrador-Horrillo, M., Lapeere, H., Meshkova, R., Pastorello, E.A., Velásquez-Lopera, M., Tamayo Quijano, L.M., Vestergaard, C., and Chapman-Rothe, N.
- Published
- 2018
- Full Text
- View/download PDF
4. Miopatías inflamatorias
- Author
-
Selva O’Callaghan, A., Trallero Araguás, E., Labrador Horrillo, M., and Grau Junyent, J.M.
- Published
- 2017
- Full Text
- View/download PDF
5. Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements
- Author
-
Giménez-Arnau, A., Ferrer, M., Bartra, J., Jáuregui, I., Labrador-Horrillo, M., Frutos, J. Ortiz de, Silvestre, J.F., Sastre, J., Velasco, M., and Valero, A.
- Published
- 2017
- Full Text
- View/download PDF
6. Práctica clínica diaria en el manejo de la urticaria crónica en España: resultados del estudio UCREX
- Author
-
Ferrer Puga M, Silvestre Salvador JF, Bartra Tomas J, Giménez-Arnau A, Labrador-Horrillo M, Miquel-Miquel J, Ortiz de Frutos FJ, Sastre Dominguez J, Valero Santiago A, Terradas-Montana P, Vidal-Jorge M, and Jáuregui Presa I
- Subjects
Urticaria ,Epidemiology ,Calidad de vida ,Dermatología ,Autoimmunity ,General Medicine ,Autoinmunidad ,Dermatology ,RC31-1245 ,RL1-803 ,Epidemiología ,Quality-of-life ,Angioedema ,Internal medicine - Abstract
Background: Chronic Urticaria (CU) is a debilitating disease whose treatment is mainly symptomatic. UCREX study aimed to identify CU patients’ profile, disease management and quality-of-life (QoL) in daily clinical practice in Spain. Methods: Observational, 12-months prospective, multicenter study, included de novo or established CU patients attending to dermatology/allergy consultations in 39 Spanish hospitals. Main variables: Urticaria Activity Score (UAS), UAS over 7 days (UAS7). Secondary variables: CU-QoL Questionnaire (CU-Q2oL), EuroQol-5 dimensions (EQ-5D), Medical Outcomes Study Sleep (MOS-Sleep) scale, Hospital Anxiety and Depression Scale (HADS). Results: 361 patients included. Of them, 176 (48.8%) considered for the main objective analysis. Mean age (SD) of 46.6 (14.2) years and 71.8% women. The year prior to inclusion, most patients (57.1%) were treated with non-sedating H1-antihistamines (NS-H1AH). At baseline, mean (SD) 3.6 (6.8) visits were registered to primary care. Mean (SD) UAS7 at baseline was 14.3 (11.0) and CU-Q2oL 24.1 (17.0) which tended to improve by 8.6 (9.7) and 13.9 (15.0), respectively, at 12-months. MOS-Sleep and EQ-5D remained steady during the study, except pain/discomfort and anxiety/depression which went from 58.7% and 49.6% to 29.6% and 26.9%, respectively. At baseline, HADS showed a mean (SD) anxiety of 8.7 (4.5) and depression 5.1 (4.4), decreasing to 7.0 (4.3) and 4.7 (4.3), respectively, at 12-months. Conclusions: Although most CU patients are treated with NS-H1AH, disease activity is still important, negatively affecting patients’ QoL, work activity and healthcare resources use. An appropriate disease management could be the basis for symptoms control, QoL improvement and resources optimization. Resumen: Antecedentes: La urticaria crónica (UC) es una enfermedad debilitante cuyo tratamiento es principalmente sintomático. El estudio UCREX tuvo como objetivo identificar el perfil de los pacientes con UC, el manejo de la enfermedad y la calidad de vida (CdV) en la práctica clínica diaria en España. Métodos: Estudio observacional, prospectivo, multicéntrico de 12 meses, que incluyó pacientes con UC de novo o establecida que acudieron a la consulta de dermatología/alergología de 39 hospitales españoles. Las variables principales fueron: el Urticaria Activity Score (UAS) y el UAS por siete días (UAS7). Las variables secundarias fueron: el cuestionario de CdV de urticaria crónica (CU-Q2oL), el EuroQol-5 Dimensiones (EQ-5D), la escala Medical Outcomes Study Sleep (MOS-Sleep) y la escala hospitalaria de ansiedad y depresión (HADS). Resultados: Se incluyeron 361 pacientes, de los cuales 176 (48,8%) formaron parte del análisis del objetivo principal. La edad media (DE) fue de 46,6 (14,2) años y el 71,8% eran del sexo femenino. El año anterior al periodo de inclusión de los pacientes, la mayoría de ellos (57,1%) se habían tratado con antihistamínicos H1 no sedantes (AHNS-H1). En la basal, se registró una media (DE) de 3,6 (6,8) de visitas a atención primaria. La media (DE) del UAS7 en la basal fue de 14,3 (11,0) y del CU-Q2oL 24,1 (17,0), observándose una tendencia en la mejoría en 8,6 (9,7) y 13,9 (15,0), respectivamente, a los 12 meses. El MOS-Sleep y el EQ-5D se mantuvieron estables durante el estudio, excepto por el dolor/malestar y la ansiedad/depresión que pasaron de 58,7 y 49,6% a 29,6 y 26,9%, respectivamente. En situación basal, el HADS mostró una ansiedad media (DE) de 8,7 (4,5) y una depresión de 5,1 (4,4), disminuyendo respectivamente a 7,0 (4,3) y 4,7 (4,3) a los 12 meses. Conclusiones: Aunque la mayoría de los pacientes son tratados con AHNS-H1, la actividad de la enfermedad sigue siendo importante, afectando negativamente a su CdV, su actividad laboral y repercutiendo negativamente en el uso de recursos sanitarios. Un manejo adecuado de la enfermedad podría ser la base para alcanzar el control de los síntomas, la mejora de la CdV y la optimización de los recursos sanitarios necesarios.
- Published
- 2022
7. Profile of omalizumab in the treatment of chronic spontaneous urticaria
- Author
-
Labrador-Horrillo M and Ferrer M
- Subjects
Therapeutics. Pharmacology ,RM1-950 - Abstract
Moises Labrador-Horrillo,1 Marta Ferrer2 1Allergy Section, Internal Medicine Department, Vall d’Hebron Hospital, Universitat Autònoma de Barcelona, Barcelona, 2Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, IDISNA, Instituto de Investigación de Navarra, Pamplona, Spain Abstract: Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely studied in the field of asthma and is currently approved for the treatment of both adult and pediatric (children; >6-year-old) patients. In addition, in recent, well-controlled clinical trials in patients with CSU resistant to antihistamines, add-on therapy with subcutaneous omalizumab significantly reduced the severity of itching, and the number and size of hives, and increased patients’ health-related QoL and the proportion of days free from angioedema compared with placebo, with an excellent tolerance. Thus, omalizumab is an effective and well-tolerated add-on therapy for patients with CSU who are symptomatic despite background therapy with H1 antihistamines. In this review, we cover the following points: epidemiology, pathogenesis, assessment of activity, impact on QoL, and treatment of CSU, and finally, we focus on omalizumab in the treatment of CSU including the pharmacokinetic properties and mechanism of action, and use in pregnant women, nursing infants, and children. Keywords: omalizumab, chronic spontaneous urticaria, antihistamines, subcutaneous administration, add-on therapy
- Published
- 2015
8. Re-Print-Anaphylaxis Induced by Beer
- Author
-
Navarro L, Lazo C, Pineda P, Labrador-Horrillo M, Roger A, and Basagaña M
- Subjects
digestive, oral, and skin physiology ,food and beverages - Abstract
The prevalence of cereal allergy is highly influenced by geographical area and consumption habits. According to data from Alergologica 2015 [1], cereal allergy accounts for 2.1% of all cases of food allergy in Spain. Beer is a barley-based alcoholic beverage that also contains hops, yeast, and other cereals (wheat, oats, corn, and even rye). Barley is also the basis of malt vinegar, whiskey, and gin. Several allergens of barley have been described, including lipid transfer protein (LTP), - and ß-amylase, gliadin, glutenin, peroxiredoxin, thionin, and trypsin inhibitor [2].
- Published
- 2022
9. Consensus on the Definition of Control and Remission in Chronic Urticaria
- Author
-
Gimenez-Arnau A, Jauregui I, Silvestre-Salvador J, Valero A, Ferrer M, Sastre J, Frutos F, Labrador-Horrillo M, Bartra J, and Miquel J
- Subjects
Terminology as topic ,Consensus ,Delphi Technique ,Immunology ,Chronic Disease ,Immunology and Allergy ,Humans ,Chronic Urticaria ,Patient outcome assessment ,Recurrence. Consensus ,Chronic urticaria ,Copper - Abstract
The terms control and remission and other key terms used in chronic urticaria (CU) such as flare-up, relapse, exacerbation, and recurrence have not been fully defined in the literature. Disease monitoring and treatment goals in clinical practice are not well established. After a qualitative appraisal of available evidence, we aimed to find a consensus definition of control and remission, clarify key terminology, provide guidance on how to monitor the disease, and establish treatment goals in clinical practice. A modified Delphi consensus approach was used. Based on a literature review, a scientific committee provided 137 statements addressing controversial definitions and terms, available patient-reported outcomes (PROs), and recommendations on how to measure therapeutic objectives in CU. The questionnaire was evaluated by 138 expert allergists and dermatologists. A consensus was reached on 105 out of the 137 proposed items (76.6%). The experts agreed that complete control and remission of CU could be defined as the absence of signs or symptoms while on treatment and in the absence of treatment, respectively. Consensus was not reached on the definition of other key terms such as flare-up, exacerbation, and recurrence. The panel agreed that the objective of therapy in CU should be to achieve complete control. PROs that define the degree of control (complete, good, partial, or absence) were established. An algorithm for disease assessment is provided. In conclusion, this work offers consensus definitions and tools that may be useful in the management of patients with CU.
- Published
- 2022
10. Immunotherapy in allergic rhinitis and lower airway outcomes
- Author
-
Cardona, V., Luengo, O., and Labrador-Horrillo, M.
- Published
- 2017
- Full Text
- View/download PDF
11. WITHDRAWN: Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study
- Author
-
Ferrer Puga, M., Silvestre Salvador, J.F., Bartra Tomas, J., Giménez-Arnau, A., Labrador-Horrillo, M., Miquel-Miquel, J., Ortiz de Frutos, F.J., Sastre Dominguez, J., Valero Santiago, A., Terradas-Montana, P., Vidal-Jorge, M., and Jáuregui Presa, I.
- Published
- 2022
- Full Text
- View/download PDF
12. [Artículo traducido] Práctica clínica diaria en el manejo de la urticaria crónica en España: resultados del estudio UCREX
- Author
-
Ferrer Puga, M., primary, Silvestre Salvador, J.F., additional, Bartra Tomas, J., additional, Giménez-Arnau, A., additional, Labrador-Horrillo, M., additional, Miquel-Miquel, J., additional, Ortiz de Frutos, F.J., additional, Sastre Dominguez, J., additional, Valero Santiago, A., additional, Terradas-Montana, P., additional, Vidal-Jorge, M., additional, and Jáuregui Presa, I., additional
- Published
- 2022
- Full Text
- View/download PDF
13. Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study
- Author
-
Ferrer Puga, M., primary, Silvestre Salvador, J.F., additional, Bartra Tomas, J., additional, Giménez-Arnau, A., additional, Labrador-Horrillo, M., additional, Miquel-Miquel, J., additional, Ortiz de Frutos, F.J., additional, Sastre Dominguez, J., additional, Valero Santiago, A., additional, Terradas-Montana, P., additional, Vidal-Jorge, M., additional, and Jáuregui Presa, I., additional
- Published
- 2022
- Full Text
- View/download PDF
14. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview
- Author
-
Matito, A, primary, Escribese, MM, additional, Longo, N, additional, Mayorga, C, additional, Luengo-Sánchez, O, additional, Pérez-Gordo, M, additional, Matheu, V, additional, Labrador-Horrillo, M, additional, and Seoane-Reula, ME, additional
- Published
- 2021
- Full Text
- View/download PDF
15. FAQS on when to use Molecular Allergy Diagnosis (MD) in clinical practice
- Author
-
Luengo, O, primary and Labrador-Horrillo, M, additional
- Published
- 2021
- Full Text
- View/download PDF
16. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia
- Author
-
Silveira, M.G., Selva-O’Callaghan, A., Ramos-Terrades, N., Arredondo-Agudelo, K.V., Labrador-Horrillo, M., and Bravo-Masgoret, C.
- Published
- 2016
- Full Text
- View/download PDF
17. WITHDRAWN: Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study
- Author
-
Ferrer Puga, M., primary, Silvestre Salvador, J.F., additional, Bartra Tomas, J., additional, Giménez-Arnau, A., additional, Labrador-Horrillo, M., additional, Miquel-Miquel, J., additional, Ortiz de Frutos, F.J., additional, Sastre Dominguez, J., additional, Valero Santiago, A., additional, Terradas-Montana, P., additional, Vidal-Jorge, M., additional, and Jáuregui Presa, I., additional
- Published
- 2021
- Full Text
- View/download PDF
18. Management of urticaria: not too complicated, not too simple
- Author
-
Ferrer, M., Bartra, J., Giménez-Arnau, A., Jauregui, I., Labrador-Horrillo, M., Ortiz de Frutos, J., Silvestre, J. F., Sastre, J., Velasco, M., and Valero, A.
- Published
- 2015
- Full Text
- View/download PDF
19. Onset of Nut Allergy in a Pediatric Cohort: Clinical and Molecular Patterns in the AFRUSEN Study
- Author
-
Ibáñez-Sandin, M D, Rodríguez Del Río, P, Alvarado, M I, García, B E, Garriga-Baraut, T, Reche Frutos, M, Escudero, C, Ramirez Jiménez, A, Vila, L, Lasa, E M, Blasco, C, Marchán-Martin, E, Martorell, A, Sanchez-García, S, Rodríguez-Álvarez, M, Infante, S, Rodríguez Vazquez, V, Olaguibel, J M, Labrador-Horrillo, M, Carrillo, T, and AFRUSEN Task Force, Pediatric Allergy Committee, Spanish Society of Allergy and Clinical Immunology (SEAIC)
- Subjects
Nut ,Component-resolved diagnosis ,Allergy ,medicine.medical_specialty ,Walnut ,Allergy onset ,Arachis ,Immunology ,Juglans ,Sensitization profile ,Food allergy ,Immunology and Allergy ,Medicine ,Humans ,Nuts ,Peanut Hypersensitivity ,Child ,Anaphylaxis ,Sensitization ,Skin Tests ,Nut allergy ,business.industry ,digestive, oral, and skin physiology ,food and beverages ,Allergens ,Immunoglobulin E ,medicine.disease ,Dermatology ,Peanut ,medicine.anatomical_structure ,Cohort ,Nut Hypersensitivity ,business - Abstract
Nut allergy is a growing problem, yet little is known about its onset in children. Objective: To characterize the onset of nut allergy in children in southern Europe. The study population comprised consecutive patients up to 14 years of age who visited allergy departments with an initial allergic reaction to peanut, tree nut, or seed. The allergy work-up included a clinical history, food challenge, skin prick testing, determination of whole-extract sIgE, and ImmunoCAP ISAC-112 assay. Of the 271 children included, 260 were first diagnosed with nut allergy at a mean age of 6.5 years and at a mean (SD) of 11.8 (21.2) months after the index reaction. The most common culprit nuts at onset were walnut (36.5%), peanut (28.5%), cashew (10.4%), hazelnut (8.5%), pistachio (5.4%), and almond (5%). Onset of peanut allergy was more frequent in children ≤6 years and walnut in those aged >6 years (P=.032). In 65% of cases, the allergic reaction occurred the first time the patient consumed the nut, and 35% of reactions were anaphylactic. Overall, polysensitization to nuts was detected by skin prick testing in 64.9% of patients, although this rate was lower among walnut-allergic children (54.7%) and peanut-allergic children (54.1%) (P6 years (P=.032). In 65% of cases, the allergic reaction occurred the first time the patient consumed the nut, and 35% of reactions were anaphylactic. Overall, polysensitization to nuts was detected by skin prick testing in 64.9% of patients, although this rate was lower among walnut-allergic children (54.7%) and peanut-allergic children (54.1%) (P In the population we assessed, the onset of nut allergy occurred around 6 years of age, slightly later than that reported in English-speaking countries. Walnut was the main trigger, followed by peanut. 2S albumin storage proteins, especially Jug r 1, were the most relevant allergens. This study will help guide management and may contribute to preventive strategies in pediatric nut allergy.
- Published
- 2021
20. Anaphylaxis Induced by Beer
- Author
-
Navarro, L, primary, Lazo, L, additional, Pineda, P, additional, Labrador-Horrillo, M, additional, Roger, A, additional, and Basagaña, M, additional
- Published
- 2021
- Full Text
- View/download PDF
21. Omalizumab for the treatment of chronic inducible urticaria in 80 patients
- Author
-
Exposito-Serrano, V, Curto-Barredo, L, Peiro, PA, Armayones, SG, Serra-Baldrich, E, Spertino, J, Orti, MB, Nart, IF, Mele-Ninot, G, Baliu-Pique, C, Cunill, AS, Labrador-Horrillo, M, Vidal, AG, Chico, NF, and Gimenez-Arnau, AM
- Published
- 2021
22. Allergy risk period to Phl p 1 and Phl p 5 in Catalonia in view of the airborne levels of Poaceae pollen and Phl p 5
- Author
-
Belmonte, J, De Linares, C, Garriga-Baraut, T, Labrador-Horrillo, M, Pedemonte, C, Baltasar-Drago, MA, Miquel-Marco, S, Padro-Casas, C, Basagana-Torrento, M, Bartra, J, Munoz-Cano, R, Bobolea, I, Campa-Falcon, N, Asensio, O, Esteso-Hontoria, O, Ferre-Ybarz, L, Farraons, L, Gazquez-Garcia, V, Vinas, M, Cortes, N, and Moncin, MDMS
- Published
- 2020
23. Omalizumab for the treatment of chronic inducible urticaria in 80 patients
- Author
-
Exposito‐Serrano, V., primary, Curto‐Barredo, L., additional, Aguilera Peiro, P., additional, Gómez Armayones, S., additional, Serra‐Baldrich, E., additional, Spertino, J., additional, Bonfill Ortí, M., additional, Figueras Nart, I., additional, Melé‐Ninot, G., additional, Baliu‐Piqué, C., additional, Sala Cunill, A., additional, Labrador‐Horrillo, M., additional, Guilabert Vidal, A., additional, Fernández Chico, N., additional, and Giménez‐Arnau, A.M., additional
- Published
- 2020
- Full Text
- View/download PDF
24. Successful Adaptation of Bee Venom Immunotherapy in a Patient Monosensitized to Api m 10
- Author
-
Ruiz-León, B, primary, Navas, A, additional, Serrano, P, additional, Espinazo, M, additional, Labrador-Horrillo, M, additional, Monsalve, RI, additional, Jurado, A, additional, and Moreno-Aguilar, C, additional
- Published
- 2020
- Full Text
- View/download PDF
25. Fatal Anaphylactic Shock Induced by Intravenous Gelatin Colloid: A Postmortem Allergological Work-up
- Author
-
Molina-Molina, GJ, primary, Carrasco-González, MD, additional, Viñas-Giménez, L, additional, Sanz-Martínez, M, additional, Galván-Blasco, P, additional, Luengo, O, additional, Guilarte, M, additional, Sala-Cunill, A, additional, Cardona, V, additional, and Labrador-Horrillo, M, additional
- Published
- 2020
- Full Text
- View/download PDF
26. Management of asthma in the emergency department: a consensus statement
- Author
-
Piñera Salmerón P, Delgado Romero J, Domínguez Ortega J, Labrador Horrillo M, Álvarez Gutiérrez FJ, Martínez Moragón E, Plaza Moral V, Álvarez Rodríguez C, and Miguel Franco J
- Abstract
The purpose of this consensus statement is to provide a tool to assist in the management of asthma in Spanish emergency departments and to improve care of patients with asthma. A multidisciplinary team of 3 emergency medicine specialists, 3 respiratory medicine specialists, and 3 allergy specialists made a list of clinical questions and chose 4 clinical practice guidelines on asthma management to prioritize when answering the questions. The team members first worked individually and then discussed their findings in a meeting to reach consensus about the content of the present statement. The recommendations and clinical algorithms in the statement contribute to detecting the asthmatic patient on arrival at the emergency department, establishing the diagnosis, following unified treatment criteria, and referring the patient to a respiratory medicine specialist, an allergy specialist, or a primary care physician, as appropriate. The definitions used in this statement provide a common language for asthma in the interest of helping to unify care practices in emergency departments. The diagnostic criteria, treatment guidelines, and criteria for discharging and admitting patients provided should be useful for managing asthma in Spanish emergency departments.
- Published
- 2018
27. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria
- Author
-
Giménez Arnau, AM, primary, Valero Santiago, A, additional, Bartra Tomás, J, additional, Jáuregui Presa, I, additional, Labrador Horrillo, M, additional, Miquel Miquel, FJ, additional, Ortiz de Frutos, J, additional, Sastre, J, additional, Silvestre Salvador, JF, additional, and Ferrer Puga, M, additional
- Published
- 2019
- Full Text
- View/download PDF
28. Anaphylaxis Induced by Conlinin, a 2S Storage Protein in Flaxseed
- Author
-
Basagaña, M, primary, Prieto-García, A, additional, Miquel, S, additional, Micozzi, S, additional, Bartolomé, B, additional, Labrador-Horrillo, M, additional, and Roger, A, additional
- Published
- 2018
- Full Text
- View/download PDF
29. Vertebrate Tropomyosin as an Allergen
- Author
-
Peixoto, S, primary, Monteiro, T, additional, Carvalho, M, additional, Santos, M, additional, Matos, C, additional, Bartolomé, B, additional, Labrador-Horrillo, M, additional, and Quaresma, M, additional
- Published
- 2018
- Full Text
- View/download PDF
30. Statin-associated autoimmune myopathy: A distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories
- Author
-
Alvarado-Cardenas, M, Marin-Sanchez, A, Martinez, MA, Martinez-Martinez, L, Pinal-Fernandez, I, Labrador-Horrillo, M, Balada, E, Mundet-Tuduri, X, Gonzalez-Mera, L, Casademont, J, Acebes, EM, Moreno, P, Juarez, C, Grau-Junyent, JM, Pujol-Borrell, R, and Selva-O'Callaghan, A
- Subjects
Statin-associated autoimmune myopathy ,Myositis ,Immunofluorescence pattern ,ELISA ,Blot ,Anti-HMGCR ,HALIP pattern - Abstract
Background and objective: Statin-associated autoimmune myopathy (SAAM) with anti-HMGCR antibodies has recently been described. Several specific immunoassays are in use to detect HMGCR antibodies. In the course of systematic autoantibody screening we recognized a new distinct IFL staining pattern on rat liver sections that regularly coincided with anti-HMGCR antibodies. In this study we investigated whether this new IFL pattern is specifically associated to statin-associated autoimmune myopathy and corresponds to anti-HMGCR antibodies. Patients and methods: Twenty-three patients positive for anti-HMGCR antibodies (14 diagnosed with SAAM) were investigated for anti-HMGCR antibodies by two ELISA assays and confirmed by immmunoblot. HMGCR associated liver IFL pattern (HALIP) was detected by indirect IFL and the reactivity against HMGCR was confirmed by immunoabsorption using purified human HMGCR antigen. 90 patients with other autoimmune diseases and 45 non-autoimmune statin treated patients were studied as controls. Results: 21 out of 23 (91%) anti-HMGCR positive patients were HALIP positive. The staining was completely and specifically removed by immunoabsorption with human purified HMGCR. None of the control sera from autoimmune patients or non-autoimmune statin treated subjects was positive for HALIP. Statistical concordance between HALIP and anti-HMGCR antibody specific tests was 98.7%, kappa 0.95. Conclusions: A new and distinct IFL staining pattern (HALIP) is associated to HMGCR associated myopathy. Absorption and concordance studies indicate that the antigen recognized in the liver by HALIP is HMGCR or a closely related protein. Awareness of this new pattern can help to detect HMGCR autoantibodies in statin treated patients tested for autoimmune serology. (C) 2016 Elsevier B.V. All rights reserved.
- Published
- 2016
31. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases
- Author
-
González‐Medina, M., primary, Curto‐Barredo, L., additional, Labrador‐Horrillo, M., additional, and Giménez‐Arnau, A., additional
- Published
- 2016
- Full Text
- View/download PDF
32. Inflammatory myopathy: diagnosis and clinical course, specific clinical scenarios and new complementary tools
- Author
-
Selva-O'Callaghan, A, Trallero-Araguas, E, Martinez, MA, Labrador-Horrillo, M, Pinal-Fernandez, I, Grau-Junyent, JM, and Juarez, C
- Subjects
polymyositis ,classification ,dermatomyositis ,autoantibodies ,diagnosis ,idiopathic inflammatory myopathies ,myositis - Abstract
Idiopathic inflammatory myopathies are a heterogeneous group of rare autoimmune diseases characterized by symmetric proximal muscle weakness and inflammatory infiltrates on muscle biopsy. A meticulously collected combination of clinical, serological, and pathological data is essential to correctly diagnose and classify myositis patients, often a considerable challenge for clinicians. This article provides a comprehensive overview of the most useful tools for the diagnosis and follow-up of patients with myositis. Capillaroscopy, serological biomarkers (particularly the autoantibody profile) and imaging techniques, such as muscle magnetic resonance and chest ultrasound, are of great aid in diagnosing, classifying and managing these patients. Relevant clinical scenarios, such as interstitial lung disease, associated cancer and pregnancy are also addressed in this review. Myositis registries, identification of new autoantibodies, and genetic studies will enhance our understanding of the pathogenesis of these conditions and help to define new diagnostic and therapeutic approaches.
- Published
- 2015
33. Immunotherapy in allergic rhinitis and lower airway outcomes
- Author
-
Cardona, V., primary, Luengo, O., additional, and Labrador-Horrillo, M., additional
- Published
- 2016
- Full Text
- View/download PDF
34. OP0009 Distinctive Immunofluorescence Pattern in Statin-Associated Autoimmune Myopathy with Anti-HMGCR Autoantibodies
- Author
-
Alvarado-Cardenas, M., primary, Marin, A., additional, Martinez, M.A., additional, Pinal-Fernandez, I., additional, Labrador-Horrillo, M., additional, Moreno, P.J., additional, Millisenda, J.C., additional, Grau, J.M., additional, Pujol, R., additional, Juárez, C., additional, and Selva-O'Callaghan, A., additional
- Published
- 2016
- Full Text
- View/download PDF
35. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia
- Author
-
Silveira, M.G., primary, Selva-O’Callaghan, A., additional, Ramos-Terrades, N., additional, Arredondo-Agudelo, K.V., additional, Labrador-Horrillo, M., additional, and Bravo-Masgoret, C., additional
- Published
- 2015
- Full Text
- View/download PDF
36. Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study
- Author
-
Ferrer Puga, M., Silvestre Salvador, J.F., Bartra Tomas, J., Giménez-Arnau, A., Labrador-Horrillo, M., Miquel-Miquel, J., Ortiz de Frutos, F.J., Sastre Dominguez, J., Valero Santiago, A., Terradas-Montana, P., Vidal-Jorge, M., and Jáuregui Presa, I.
- Abstract
Chronic Urticaria (CU) is a debilitating disease whose treatment is mainly symptomatic. UCREX study aimed to identify CU patients’ profile, disease management and quality-of-life (QoL) in daily clinical practice in Spain.
- Published
- 2021
- Full Text
- View/download PDF
37. PRÁCTICA CLÍNICA DIARIA EN EL MANEJO DE LA URTICARIA CRÓNICA EN ESPAÑA: RESULTADOS DEL ESTUDIO UCREX
- Author
-
Ferrer, M., Silvestre, J.F., Bartra, Joan, Giménez-Arnau, A., Labrador-Horrillo, M., Miquel-Miquel, J., de Frutos, J.F. Ortiz, Sastre, J., Valero, A., Terradas-Montaña, P., Vidal-Jorge, M., and Jauregui, I.
- Abstract
Antecedentes: la urticaria crónica (UC) es una afectación cuyo tratamiento es principalmente sintomático. El estudio UCREX tuvo como objetivo identificar el perfil de los pacientes con UC, el manejo de la enfermedad y la calidad de vida (CdV) en la práctica clínica diaria en España.
- Published
- 2021
- Full Text
- View/download PDF
38. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases.
- Author
-
González ‐ Medina, M., Curto ‐ Barredo, L., Labrador ‐ Horrillo, M., and Giménez ‐ Arnau, A.
- Subjects
CHRONIC diseases ,ADRENOCORTICAL hormones ,HORMONE therapy ,PREGNANCY complications ,DISEASE exacerbation - Abstract
The article presents case studies involving chronic spontaneous urticaria (CSU). It mentions that first patient, which developed severe exacerbations, received treatment with short courses of oral corticosteroid. It mentions that second patient developed a sudden worsening during pregnancy despite treatment with omalizumab. It reveals that two cases were reported to the official pharmacosurveillance system.
- Published
- 2017
- Full Text
- View/download PDF
39. Angioedema severity and impact on quality of life: Chronic histaminergic angioedema versus chronic spontaneous urticaria
- Author
-
Nuria Rodríguez-Garijo, Marina Sabaté-Brescó, Julián Azofra, Maria Luisa Baeza, Camen Diaz Donado, Pere Gaig, Mar Guilarte, Valeria Herrera-Lasso, Moisés Labrador-Horrillo, Anna Sala-Cunill, Beatriz Veleiro, Maria Pilar Gil, Marta Ferrer, Institut Català de la Salut, [Rodríguez-Garijo N] Department of Dermatology, Clinica Universidad de Navarra, Pamplona, Spain. [Sabaté-Brescó M] Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain. Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain. RETIC de Asma, Reacciones Adversas y Alérgicas, Spain. [Azofra J, Donado CD] Allergy Section, Hospital Universitario Central de Asturias, Oviedo, Spain. [Baeza ML] RETIC de Asma, Reacciones Adversas y Alérgicas, Spain. Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Biomedical Research Network on Rare Diseases (CIBERER)-U761, Gregorio Marañón Health Research Institute, Madrid, Spain. [Gaig P] Allergy Section, Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Tarragona, Spain. [Guilarte M, Labrador-Horrillo M] RETIC de Asma, Reacciones Adversas y Alérgicas, Spain. Secció d’Al·lèrgia, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Quality of life ,Urticaria ,Chronic histaminergic angioedema ,Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Urticaria [DISEASES] ,afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crónica [ENFERMEDADES] ,Chronic spontaneous urticaria ,Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE] ,enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::urticaria::angioedema [ENFERMEDADES] ,Chronic Disease ,Quality of Life ,Immunology and Allergy ,Humans ,Malalties cròniques ,Chronic Urticaria ,Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Urticaria::Angioedema [DISEASES] ,Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [DISEASES] ,Angioedema ,enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::urticaria [ENFERMEDADES] ,Urticària ,Qualitat de vida - Avaluació ,ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD] - Abstract
Histamine-mediated angioedema is the most frequent form of angioedema. It is classified as idiopathic histaminergic acquired angioedema (IH-AAE)1 when allergies and other causes have been excluded and a positive treatment response to antihistamines, corticosteroids, or omalizumab has been reported. Idiopathic histaminergic acquired angioedema may occur in isolation, when it is termed chronic histaminergic angioedema (CHA), or it may be associated with wheals in chronic spontaneous urticaria angioedema (CSU-AE). The term CHA is equivalent to IH-AAE and mast cell-mediated angioedema. However, this term reflects the chronic and recurrent course of the disease. Therefore, we propose that the term CHA be internationally discussed in the following guidelines. Chronic spontaneous urticaria is classically characterized by the presence of recurrent episodes of wheals (hives) with or without angioedema for at least 6 weeks.2 Chronic histaminergic angioedema is typically considered a subtype of CSU without wheals. However, a recent study3 found several features that differentiate CHA from CSU, which suggests that CHA is a separate entity. Quality of life (QoL) studies specifically for CHA patients have not been performed, and their QoL has been assessed only in the context of CSU-AE.
- Published
- 2022
40. INMUNOCAT Study: the impact of molecular diagnosis on immunotherapy prescription in pollen polysensitized patients from Catalonia
- Author
-
Moises Labrador-Horrillo, Teresa Garriga-Baraut, Mercè Tena, M.M. San Miguel Moncín, Institut Català de la Salut, [Garriga-Baraut T, Labrador-Horrillo M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [San Miguel Moncín MM] Pius Hospital de Valls, Hospital del Vendrell Tarragona, Barcelona, Spain. [Tena M] Thermo Fisher Scientific, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Molecular Diagnostic Techniques [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Al·lèrgia - Tractament ,Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas de diagnóstico molecular [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Immunoteràpia ,enfermedades del sistema inmune::hipersensibilidad [ENFERMEDADES] ,Immune System Diseases::Hypersensitivity [DISEASES] ,Diagnòstic molecular - Abstract
Background: Recognition of specific allergens triggering immune response is key for the appropriate prescription of allergen-specific immunotherapy (SIT). This study aimed at evaluating the impact of using the commercially available microarray ImmunoCAP ISAC 112 (Thermo Fisher Scientific) on the etiological diagnosis and SIT prescription compared to the conventional diagnostic methods in patients with allergic rhinitis/rhinoconjunctivitis and/or asthma. Methods: 300 patients with respiratory allergic disease, sensitized to three or more pollen aeroallergens from different species, as assessed by skin prick-test (SPT) and specific IgE assays (sIgE), were included in this multicentric, prospective observational study. SPT and a blood test were performed to all patients. Total serum IgE, sIgE (ImmunoCAP ) for allergens found positive in the SPT and sIgE allergen components (ImmunoCAP ISAC 112) were measured. Results: According to SPT results, the most prevalent pollen sensitizers in our population were Olea europaea followed by grass, Platanus acerifolia and Parietaria judaica. The molecular diagnosis (MD) revealed Ole e 1 as the most prevalent pollen sensitizer, followed by Cup a 1, Phl p 1, Cyn d 1, Par j 2, Pla a 1, 2, and 3 and Phl p 5. Immunotherapy prescription changed, due to MD testing, in 51% of the cases, with an increase of prescription of SIT from 39% to 65%. Conclusion: The identification of the allergen eliciting the respiratory disease is essential for a correct immunotherapy prescription. The advances in allergen characterization using methods such as the commercial microarray ImmunoCAP ISAC 112 can help clinicians to improve SIT prescription.
- Published
- 2022
41. Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases
- Author
-
Olivera-Ardid, Sara, Bello-Gil, Daniel, Tuzikov, Alexander, Araujo, Ricardo N., Ferrero-Alves, Yara, García Figueroa, Blanca Esther, Labrador Horrillo, Moises, García-Pérez, Ana L., Bovin, Nicolai, Mañez, Rafael, Universitat Autònoma de Barcelona. Departament de Medicina, Institut Català de la Salut, [Olivera-Ardid S, Bello-Gil D, Ferrero-Alves Y] RemAb Therapeutics, Mòdul de Recerca B, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Tuzikov A] Department of Chemical Biology of Glycans and Lipids, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences (RAS), Moscow, Russia. [Araujo RN] Laboratório de Artrópodes Hematófagos, Departamento de Parasitologia, ICB/UFMG, Belo Horizonte, Brazil. [García Figueroa BE] MEGA: Asthma Inception and Progression Mechanisms, Complejo Hospitalario de Navarra (CHN), Pamplona, Spain. Instituto de investigación sanitaria de Navarra (IdiSNA), Pamplona, Spain. ARADyAL Research Network, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Labrador-Horrillo M] ARADyAL Research Network, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Secció d’Al•lèrgia, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Àrea de Malalties Immunomediades i Teràpies Innovadores, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Al·lèrgia ,Allergy ,Immunology ,Immunoteràpia ,αGal-syndrome ,Immunotheraphy ,Poly-l-lysine-based αGal-glycoconjugates ,Mice ,Immunology and Allergy ,Animals ,Humans ,Polylysine ,Ratolins ,Eukaryota::Animals::Chordata::Vertebrates::Mammals::Eutheria::Rodentia::Muridae::Murinae::Mice [ORGANISMS] ,hidratos de carbono::glicoconjugados [COMPUESTOS QUÍMICOS Y DROGAS] ,Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Food Hypersensitivity [DISEASES] ,GalT-KO mice ,Anti-αgal IgE inhibition ,Immunoglobulin E ,Carbohydrates::Glycoconjugates [CHEMICALS AND DRUGS] ,Al·lèrgia alimentària ,Immunoglobulin M ,Glicoconjugats ,Immunoglobulin G ,Immunotherapy ,Eukaryota::animales::Chordata::vertebrados::mamíferos::Eutheria::Rodentia::Muridae::Murinae::ratones [ORGANISMOS] ,Glycoconjugates ,Food Hypersensitivity ,enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::hipersensibilidad a los alimentos [ENFERMEDADES] - Abstract
Anti-αGal IgE antibodies mediate a spreading allergic condition known as αGal-syndrome (AGS). People exposed to hard tick bites are sensitized to αGal, producing elevated levels of anti-αGal IgE, which are responsible for AGS. This work presents an immunotherapy based on polymeric αGal-glycoconjugates for potentially treating allergic disorders by selectively inhibiting anti-αGal IgE antibodies. We synthesized a set of αGal-glycoconjugates, based on poly-L-lysine of different degrees of polymerization (DP1000, DP600, and DP100), to specifically inhibit in vitro the anti-αGal IgE antibodies in the serum of αGal-sensitized patients (n=13). Moreover, an animal model for αGal sensitization in GalT-KO mice was developed by intradermal administration of hard tick’ salivary gland extract, mimicking the sensitization mechanism postulated in humans. The in vitro exposure to all polymeric glycoconjugates (5-10-20-50-100 µg/mL) mainly inhibited anti-αGal IgE and IgM isotypes, with a lower inhibition effect on the IgA and IgG, respectively. We demonstrated a differential anti-αGal isotype inhibition as a function of the length of the poly-L-lysine and the number of αGal residues exposed in the glycoconjugates. These results defined a minimum of 27 αGal residues to inhibit most of the induced anti-αGal IgE in vitro. Furthermore, the αGal-glycoconjugate DP1000-RA0118 (10 mg/kg sc.) showed a high capacity to remove the anti-αGal IgE antibodies (≥75% on average) induced in GalT-KO mice, together with similar inhibition for circulating anti-αGal IgG and IgM. Our study suggests the potential clinical use of poly-L-lysine-based αGal-glycoconjugates for treating allergic disorders mediated by anti-αGal IgE antibodies. Copyright © 2022 Olivera-Ardid, Bello-Gil, Tuzikov, Araujo, Ferrero-Alves, García Figueroa, Labrador-Horrillo, García-Pérez, Bovin and Mañez.
- Published
- 2022
42. Milk and cow’s meat allergy in a child: A clinical case
- Author
-
Marques, Maria Luís, Falcão, Inês, Labrador Horrillo, Moisés, Falcão, Helena, Cunha, Leonor, Institut Català de la Salut, [Marques ML, Falcão I, Falcão H, Cunha L] Allergy and Clinical Immunology Department. Hospital Geral de Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal. [Labrador-Horrillo M] Secció d’Al·lèrgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Food Hypersensitivity [DISEASES] ,Immunology ,Other subheadings::/diagnosis [Other subheadings] ,Otros calificadores::/diagnóstico [Otros calificadores] ,Immunology and Allergy ,food and beverages ,Al·lèrgia alimentària - Diagnòstic ,Persons::Age Groups::Child::Child, Preschool [NAMED GROUPS] ,personas::Grupos de Edad::niño::niño preescolar [DENOMINACIONES DE GRUPOS] ,Infants ,enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::hipersensibilidad a los alimentos [ENFERMEDADES] - Abstract
Albúmina sèrica bovina; Al·lèrgia alimentària; Al·lèrgia a la carn Albúmina sérica bovina; Alergia a la comida; Alergia a la carne Bovine serum albumin; Food allergy; Meat allergy Allergy to bovine serum albumin is the main predictor of beef allergy associated with cow’s milk proteins allergy. We report a case of a 3-year-old child with cow’s milk proteins allergy since the age of 6 months who, after some ingestions of beef, developed episodes of irritability, urticaria and syncope. Specific IgE to beef, oral food challenge with medium rare cooked beef and specific IgE to bovine serum albumin were all positive, but an oral food challenge with well cooked beef was tolerated. Allergy to bovine serum albumin is not usually associated with severe reactions, since it is a thermolabile protein, however, the process of cooking meat may be insufficient to have an effect on the complex matrix of meat and associated serum albumins. The irregular pattern of the episodes and the previous diagnosis of cow’s milk proteins allergy may act as confounding factos leading to a delayed diagnosis.
- Published
- 2021
43. Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients
- Author
-
Emily Toscano-Guerra, Mónica Martínez-Gallo, Iria Arrese-Muñoz, Anna Giné, Noelia Díaz-Troyano, Pablo Gabriel-Medina, Mar Riveiro-Barciela, Moisés Labrador-Horrillo, Fernando Martinez-Valle, Adrián Sánchez Montalvá, Manuel Hernández-González, Ricardo Pujol Borrell, Francisco Rodríguez-Frias, Roser Ferrer, Timothy M. Thomson, Rosanna Paciucci, Institut Català de la Salut, [Toscano-Guerra E] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Laboratori de Senyalització Cel•lular i Progressió del Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universidad Peruana Cayetano Heredia, Lima, Perú. [Martínez-Gallo M, Arrese-Muñoz I, Hernández-González M, Pujol Borrell R] Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Giné A, Paciucci R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Laboratori de Senyalització Cel•lular i Progressió del Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Díaz-Troyano N, Gabriel-Medina P, Rodríguez-Frias F, Ferrer R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Riveiro-Barciela M, Labrador-Horrillo M, Martinez-Valle F] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Montalvá AS] Servei de Malalties Infeccioses, Centre de Salut Internacional i Malalties Transmissibles Drassanes - Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Consejo Superior de Investigaciones Científicas (España), Generalitat de Catalunya, and Instituto de Salud Carlos III
- Subjects
Male ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Survival ,Coronavirus disease 2019 (COVID-19) ,COVID19 ,Immune phenotype ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Disease ,Asymptomatic ,COVID-19 (Malaltia) ,Immunophenotyping ,Diabetes mellitus ,Internal medicine ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Humans ,Medicine ,Testosterone ,Androstenedione ,Testosterona ,Serum testosterone ,Gynecology ,SARS-CoV-2 ,business.industry ,COVID-19 ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,Testosterone (patch) ,General Medicine ,Luteinizing Hormone ,medicine.disease ,Institutional review board ,Otros::Otros::masculino [Otros] ,Other::Other::Male [Other] ,Homes ,compuestos policíclicos::compuestos con anillos de fusión::esteroides::androstanos::androstenos::androstenoles::testosterona [COMPUESTOS QUÍMICOS Y DROGAS] ,Male patient ,Androgens ,Longitudinal ,Female ,medicine.symptom ,Luteinizing hormone ,Polycyclic Compounds::Fused-Ring Compounds::Steroids::Androstanes::Androstenes::Androstenols::Testosterone [CHEMICALS AND DRUGS] ,business - Abstract
Background SARS-CoV-2 infection portends a broad range of outcomes, from a majority of asymptomatic cases to a lethal disease. Robust correlates of severe COVID-19 include old age, male sex, poverty, and co-morbidities such as obesity, diabetes, and cardiovascular disease. A precise knowledge of the molecular and biological mechanisms that may explain the association of severe disease with male sex is still lacking. Here, we analyzed the relationship of serum testosterone levels and the immune cell skewing with disease severity in male COVID-19 patients. Methods Biochemical and hematological parameters of admission samples in 497 hospitalized male and female COVID-19 patients, analyzed for associations with outcome and sex. Longitudinal (in-hospital course) analyses of a subcohort of 114 male patients were analyzed for associations with outcome. Longitudinal analyses of immune populations by flow cytometry in 24 male patients were studied for associations with outcome. Results We have found quantitative differences in biochemical predictors of disease outcome in male vs. female patients. Longitudinal analyses in a subcohort of male COVID-19 patients identified serum testosterone trajectories as the strongest predictor of survival (AUC of ROC = 92.8%, p < 0.0001) in these patients among all biochemical parameters studied, including single-point admission serum testosterone values. In lethal cases, longitudinal determinations of serum luteinizing hormone (LH) and androstenedione levels did not follow physiological feedback patterns. Failure to reinstate physiological testosterone levels was associated with evidence of impaired T helper differentiation and augmented circulating classical monocytes. Conclusions Recovery or failure to reinstate testosterone levels is strongly associated with survival or death, respectively, from COVID-19 in male patients. Our data suggest an early inhibition of the central LH-androgen biosynthesis axis in a majority of patients, followed by full recovery in survivors or a peripheral failure in lethal cases. These observations are suggestive of a significant role of testosterone status in the immune responses to COVID-19 and warrant future experimental explorations of mechanistic relationships between testosterone status and SARS-CoV-2 infection outcomes, with potential prophylactic or therapeutic implications., This study was funded by grants from the Ministerio de Ciencia e Innovación (RTI2018-096055-B-I00), Consejo Superior de Investigaciones Científicas’ COVID-19 Research Fund (CSIC-COV19-006, CSIC-COV19-201), Agència de Gestió d’Ajuts Universitaris i de Recerca (2020PANDE00048 and 2017SGR 1411 GRC), and Plan Nacional de I+D (PID-107139RB-C21) and Instituto Nacional de la Salud Carlos III (PI18/00346 and COVID-19_00416).
- Published
- 2021
44. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study)
- Author
-
Cristina Ballesteros, J.F. Silvestre, Manuel Velasco, Moises Labrador-Horrillo, Marta Ferrer, Joan Bartra, Joaquín Sastre, Antonio Valero, Javier Ortiz de Frutos, Ana Giménez-Arnau, Ignacio Jáuregui, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Institut Català de la Salut, [Jauregui I] Allergy Department, Hospital Universitario Basurto, Bilbao, Spain. [Gimenez-Arnau A] Dermatology Department, Hospital del Mar, Parc de Salut Mar, Universitat Autonoma Barcelona, Barcelona, Spain. [Bartra J] Allergy Unit, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Labrador-Horrillo M] Servei d’Al•lergologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Ortiz de Frutos J] Dermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. [Silvestre JF] Dermatology Department, Hospital General Universitario de Alicante, Alicante, Spain., Hospital Universitari Vall d'Hebron, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,Disciplinas y Actividades Conductuales::Pruebas Psicológicas::Psicometría [PSIQUIATRÍA Y PSICOLOGÍA] ,Urticaria ,Spanish ,Severity of Illness Index ,Quality of life ,Prospective Studies ,Spanish version ,General Medicine ,Middle Aged ,Chronic urticaria ,Reliability ,Skin and Connective Tissue Diseases::Skin Diseases::Skin Diseases, Vascular::Urticaria [DISEASES] ,Clinical Practice ,Convergent validity ,Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] ,lcsh:R858-859.7 ,Female ,Behavioral Disciplines and Activities::Psychological Tests::Psychometrics [PSYCHIATRY AND PSYCHOLOGY] ,medicine.symptom ,Psicometria ,Urticària ,Psychometric ,Adult ,medicine.medical_specialty ,Psychometrics ,Técnicas de Investigación::Métodos Epidemiológicos::Recolección de Datos::Encuestas y Cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Medicina ,Qüestionaris ,lcsh:Computer applications to medicine. Medical informatics ,Validity ,Cronbach's alpha ,medicine ,Humans ,Translations ,Patient Reported Outcome Measures ,Aged ,Angioedema ,business.industry ,Questionnaire ,Research ,Public Health, Environmental and Occupational Health ,Reproducibility of Results ,Construct validity ,técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Spain ,Chronic Disease ,Quality of Life ,Physical therapy ,Enfermedades de la Piel y Tejido Conjuntivo::Enfermedades de la Piel::Enfermedades Cutáneas Vasculares::Urticaria [ENFERMEDADES] ,Observational study ,business - Abstract
Background: The daily diary Urticaria Activity Score (UAS) and its weekly score (UAS7) are widely used to assess signs and symptoms in patients with chronic spontaneous urticaria (CSU). The objective of this study was to assess the psychometric properties of a Spanish version of the once-daily UAS. Methods: Observational study in patients ≥18 years old receiving usual care for CSU (daily or almost daily occurrence of generalized hives or angioedema for ≥6 weeks). Patients were included consecutively and completed the UAS, EQ-5D, and the Chronic Urticaria Quality of Life scale (CU-Q2oL) at two study visits 6 weeks apart. On each occasion, the UAS was completed once-daily for 7 consecutive days to be able to calculate the UAS7 score. Psychometric properties of reliability, construct validity, and responsiveness were assessed. The Minimal Important Difference (MID) was estimated for the UAS7 using anchor- and distribution-based approaches. Results: Data from 166 patients was available for analysis (mean age 49 years, 65.7% female). Floor (5.4% of patients with the lowest possible score) and ceiling (1.2%) effects were low; 15% of patients had missing values. Internal consistency and test-retest reliability were good (Cronbach's alpha of 0.83 and an ICC of 0.84, respectively). Convergent validity was demonstrated through the pattern of correlations with the EQ-5D and CU-Q2oL and known groups' validity was demonstrated by the instrument's ability to discriminate between patients with different overall levels of urticaria severity, with between-group effect-sizes (ES) ranging from 0.36 to 1.19. The UAS7 proved responsive to change with effect sizes ranging from 0.3 to 1.52 in patients reporting improvement or deterioration in overall urticaria status. The MID for the UAS7 score was estimated at 7-8 points, on a scale of 0-42. Conclusions: The Spanish version of the UAS score has demonstrated a robust psychometric performance in patients with CSU managed in conditions of usual care. It can therefore be considered a suitable instrument to assess disease activity in clinical practice in Spanish-speaking patients. The Spanish version's reliability and validity are similar to those reported for other language versions of the once- and twice-daily variants of the UAS., Funding for the EVALUAS Study was provided by Novartis Pharmaceuticals, Spain
- Published
- 2019
45. Unraveling wasp sensitization in a patient with systemic mastocytosis by CAP-inhibition assay.
- Author
-
Valero H, Luengo O, Cardona V, Pereira J, and Labrador-Horrillo M
- Subjects
- Humans, Male, Animals, Desensitization, Immunologic methods, Allergens immunology, Allergens administration & dosage, Tryptases blood, Immunoglobulin E immunology, Immunoglobulin E blood, Wasp Venoms immunology, Mastocytosis, Systemic diagnosis, Mastocytosis, Systemic immunology, Mastocytosis, Systemic complications, Anaphylaxis diagnosis, Anaphylaxis immunology, Anaphylaxis etiology, Insect Bites and Stings immunology, Insect Bites and Stings diagnosis, Insect Bites and Stings complications, Wasps immunology, Cross Reactions immunology
- Abstract
Systemic mastocytosis (SM) is a clonal mast cell disorder that can lead to potentially severe anaphylactic reactions. Hymenoptera sting is one of the most frequent triggers of anaphylaxis in these patients, and diagnosis of indolent SM (ISM) without skin involvement (ISMs) is not rare. In this subgroup of patients, venom immunotherapy (VIT) is an effective treatment decreasing subsequent systemic reactions, and lifelong administration is recommended. An individualized diagnosis is necessary to offer the most adequate VIT, and molecular diagnosis (MD) may be useful to discriminate between primary sensitization and cross-reactivity. Nevertheless, other techniques such as ImmunoCAP inhibition assays may be necessary to identify the genuine sensitization to offer the most suitable VIT. We present a male patient with an anaphylactic reaction following several wasp stings. The patient was diagnosed with ISM, and allergy to both Polistes dominula and Vespula sp venom was confirmed. In this scenario, MD did not discriminate between a genuine double sensitization and venom cross-reactivity between both vespids. Thus, CAP-inhibition assay was performed. This case indicated the importance of an accurate diagnosis of hymenoptera venom allergy (HVA). It also highlights the usefulness of CAP-inhibition assays when MD fails to distinguish between genuine double Polistes-Vespula sensitization and cross-reactivity., Competing Interests: The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
46. A real-life ImmunoCAT study: impact of molecular diagnosis through ImmunoCAP TM ISAC 112 on immunotherapy prescription in pollen-polysensitized patients in Catalonia, Spain.
- Author
-
Garriga-Baraut T, Labrador-Horrillo M, Tena M, Linares C, Esteso-Hontoria O, Pedemonte C, Basagaña-Torrento M, Miquel S, Padró-Casas C, Campa-Falcon N, Ferré-Ybarz L, Gázquez-Garcia V, Muñoz-Cano R, Viñas M, Farrarons L, Baltasar-Dragó M, Cortés N, Asensio O, Bartra J, Belmonte J, Bobolea I, Raga E, and Moncín MSM
- Subjects
- Humans, Female, Spain, Adolescent, Male, Child, Prospective Studies, Young Adult, Adult, Child, Preschool, Immunoglobulin E immunology, Immunoglobulin E blood, Skin Tests, Molecular Diagnostic Techniques, Pollen immunology, Allergens immunology, Allergens administration & dosage, Desensitization, Immunologic methods, Rhinitis, Allergic, Seasonal diagnosis, Rhinitis, Allergic, Seasonal immunology, Rhinitis, Allergic, Seasonal therapy
- Abstract
Background: Molecular diagnosis in allergology helps to identify multiple allergenic molecules simultaneously. The use of purified and/or recombinant allergens increases the accuracy of individual sensitization profiles in allergic patients., Objective: To assess the impact of molecular diagnosis through the ImmunoCAP
TM ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species., Methods: A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient's clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAPTM ISAC® 112 to recombinant and/or purified allergen components., Results: A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray., Conclusions: Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT., Competing Interests: M.L-H report research funding from Thermofisher. None of the other authors have anything to disclose.- Published
- 2024
- Full Text
- View/download PDF
47. Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema.
- Author
-
Gil-Serrano J, Labrador-Horrillo M, Galvan-Blasco P, Sala-Cunill A, Bigas P, Pereira-González J, Luengo O, Cardona V, and Guilarte M
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Aged, Adolescent, Child, Young Adult, Aged, 80 and over, Complement C1 Inhibitor Protein genetics, Complement C1 Inhibitor Protein metabolism, Serum Amyloid A Protein metabolism, Factor XII genetics, Factor XII metabolism, Blood Sedimentation, Inflammation Mediators blood, Fibrin Fibrinogen Degradation Products metabolism, Fibrin Fibrinogen Degradation Products analysis, Angioedemas, Hereditary blood, Angioedemas, Hereditary diagnosis, Biomarkers blood, Inflammation blood
- Abstract
Background: Hereditary angioedema (HAE) is a rare disease characterized by localized and self-limited angioedema (AE) attacks. A local increase of bradykinin (BK) mediates AE attacks in HAE, however the role of inflammation in HAE has been poorly explored We aim to analyze the role of inflammatory mediators in HAE patients during AE attacks., Methods: Patients with a confirmed HAE diagnosis due to C1 inhibitor deficiency (HAE-C1INH) or patients F12 gene mutations (HAE-FXII) attending to our outpatient clinic between November-2019 and May-2022 were included. Demographic and clinical characteristics were analyzed. Blood samples were collected both during symptom-free periods (baseline) and during HAE attacks, and acute phase reactants (APR), such as serum amyloid A (SAA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-Dimer and white blood cells were measured., Results: Seventy-eight patients were enrolled in the study, with a predominant representation of women (76%, n=59), and a mean age of 47.8 years (range 6-88). Among them, 67% (n=52) of patients had HAE-C1INH (46 classified as type 1 and 6 as type 2) while 33% (n=26) had HAE-FXII. During attack-free periods, the majority of patients exhibited normal levels of SAA, ESR, D-dimer, ACE and WCC. However, in a subset of patients (16% for SAA, 18% for ESR, and 14.5% for D-dimer), elevations were noted at baseline. Importantly, during HAE attacks, significant increases were observed in SAA in 88% of patients (p< 0.0001 vs. baseline), in ESR in 65% (p= 0.003 vs. baseline) and D-dimer in 71% (p=0.001 vs . baseline) of the patients. A comparison between baseline and acute attack levels in 17 patients revealed significant differences in SAA AA (p<0. 0001), ESR (p<0.0001) and D-dimer (p= 0.004). No significant differences were observed in CRP (p=0.7), ACE (p=0.67) and WCC (p=0.54). These findings remained consistent regardless of HAE type, disease activity or location of angioedema., Conclusion: The systemic increase in APR observed during HAE attacks suggests that inflammation extends beyond the localized edematous area. This finding underscores the potential involvement of inflammatory pathways in HAE and highlights the need for further investigation into their role in the pathophysiology of HAE., Competing Interests: JG-S has received support for attending meetings from CSL Behring and Takeda. ML-H has received honoraria for educational purposes and/or support for attending meetings from CSL Behring and Takeda. PG-B has received honoraria for educational purposes and/or support for attending meetings from CSL Behring and Takeda. AS-C has received consulting fees, honoraria for educational purposes and/or support for attending meetings from CSL Behring, Kalvista and Takeda. VC has received support for attending meetings from BioCryst. MG has received consulting fees, honoraria for educational purposes and/or support for attending meetings from Biocryst, Biomarin, CSL Behring, Kalvista, Pharming, Pharvaris and Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest., (Copyright © 2024 Gil-Serrano, Labrador-Horrillo, Galvan-Blasco, Sala-Cunill, Bigas, Pereira-González, Luengo, Cardona and Guilarte.)
- Published
- 2024
- Full Text
- View/download PDF
48. Challenging dogmas: Intravenous versus oral beta-lactam antibiotic provocation tests.
- Author
-
Molina-Molina GJ, Gómez-Duque M, Vidal Guitart X, Agustí Escasany A, Labrador-Horrillo M, Luengo O, Sala-Cunill A, Galvan-Blasco P, Guilarte M, and Cardona V
- Abstract
Background: Drug provocation tests (DPT) are considered the gold standard procedure to ascertain the diagnosis of beta-lactam (BL) allergy. Regarding route of administration, current recommendations prioritize oral challenges, considering them safer, and reserving the intravenous route for drugs for which this is the only formulation., Objective: To compare in terms of tolerance and safety two protocols of BL DPT, using an oral protocol (OR-DPT) and an intravenous protocol (IV-DPT)., Methods: A descriptive, retrospective study was performed, including adult patients who underwent IV-DPT or OR-DPT for suspected immediate or delayed hypersensitivity to BL antibiotics, over a period of 4 years (between January 2018 and December 2021). Demographical data, index hypersensivity reactions' characteristics and tolerance to DPT were reviewed., Results: A total of 1036 patients underwent DPT, mean age of 56.8 (standard deviation, SD, 17.8) years, 655 were women (63.2%). Immediate drug hypersensitivity reactions (DHR) had occurred in 564 of patients (54.4%). OR-DPT were performed in 439 (42.4%) and IV-DPT in 597 (57.6%). The frequency of reactions during DPT, regardless of the route used, was low (3.6%): only 16 (3.6%) in OR-DPT and 21 (3.5%) in IV-DPT. From IV-DPT, 16 out 21 DHR during DPT were immediate compared with 4 out of 16 in OR-DPT. Adjusted relative risk of developing a hypersensitivity reaction during IV-DPT versus OR-DPT was 1.13 (95% confidence interval (CI)0.57-2.22)., Conclusion: The results suggest that OR-DPT and IV-DPT are both safe procedures when adequately performed. However, IV-DPT protocols showed a higher rate of immediate DHR during DPT probably due to the selection of basal high-risk patients to undergo IV-DPT. In conclusion, IV-DPT may be considered as an option for challenges in drug-allergy studies, entailing a precise administration., Competing Interests: Gustavo-Jorge Molina-Molina MD: The author report no competing interests. Manuel Gómez-Duque MD: The author report no competing interests. Xavier Vidal Guitart MD PhD: The author report no competing interests. Antònia Agustí Escasany MD PhD: The author report no competing interests. Moisés Labrador-Horrillo MD PhD: The author report no competing interests. Olga Luengo MD PhD: The author report no competing interests. Anna Sala-Cunill MD PhD: The author report no competing interests. Paula Galván Blasco MD: The author report no competing interests. Mar Guilarte MD PhD: The author report no competing interests. Victoria Cardona MD PhD: The author report no competing interests., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
49. Allergy to Gibberellin-regulated proteins in an adolescent: A case of orange-induced anaphylaxis mediated by cofactors.
- Author
-
Kàtcheff SC, Labrador-Horrillo M, Bartolomé B, and Garriga-Baraut T
- Subjects
- Humans, Adolescent, Gibberellins adverse effects, Allergens, Antigens, Plant, Anaphylaxis diagnosis, Anaphylaxis etiology, Citrus sinensis, Food Hypersensitivity diagnosis
- Abstract
This report is a case of anaphylaxis in an adolescent due to allergy to gibberellin-regulated proteins mediated by cofactors, in probable relation to a pollen/food allergy syndrome. It should also emphasizes the importance of obtaining a faithful clinical history, especially when it comes to adolescent patients as they tend to initiate toxic habits., Competing Interests: We declare that we do not have any financial or personal relationship concerning the submitted publication.
- Published
- 2024
- Full Text
- View/download PDF
50. Serum Amyloid A as a Potential Biomarker for Disease Activity in Chronic Spontaneous Urticaria.
- Author
-
Carvallo A, Veleiro B, Sabaté-Brescó M, Baeza ML, Guilarte M, Herrera-Lasso V, Rodríguez-Garijo N, Diaz Donado C, Labrador-Horrillo M, and Ferrer M
- Subjects
- Humans, Serum Amyloid A Protein therapeutic use, Chronic Disease, Biomarkers, Urticaria diagnosis, Chronic Urticaria
- Abstract
Background: Chronic spontaneous urticaria (CSU) is an inflammatory skin disease with a complex physiopathology. Serum amyloid A (SAA), an acute-phase reactant, has been proposed as a potential biomarker in urticaria but has yet to be studied in a population with CSU or correlated with disease activity as indicated by the Urticaria Activity Score summed over 7 days (UAS7)., Objective: We sought to determine SAA-1 levels in patients with CSU and correlate them with its activity and control, as well as with clinical features of CSU and other potential blood biomarkers., Methods: We conducted a retrospective multicenter study of 67 patients with CSU, from whom we obtained demographic and clinical data, UAS7 as an indicator of CSU activity, and blood and serum markers., Results: SAA-1 levels positively correlated with UAS7 (r
s = 0.47, P < .001). SAA-1 levels were higher in patients with noncontrolled (UAS7 > 6) CSU than in those with controlled (UAS ≤ 6) CSU (P < .001) and were also higher in patients with concomitant angioedema (P = .003) or delayed pressure urticaria (P = .003)., Conclusion: We propose SAA-1 as a potential biomarker for activity in CSU. Further studies are required to evaluate its potential role as a biomarker for other CSU outcomes, such as response to treatment., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.